Denali Therapeutics (DNLI) Financials

$22.28

$-0.52 (-2.28%)

As on 04-Sep-2026 16:26EDT

Market cap

$3,561 Mln

Revenue (TTM)

$4 Mln

P/E Ratio

--

P/B Ratio

4.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	3.60	--	--	330.53	108.46	48.66
Cost of Revenue	107.75	11.18	7.80	16.73	7.03	5.61
Gross Profit	-104.15	-11.18	-7.80	330.53	108.46	48.66
Operating Expenses	540.50	544.16	487.34	527.23	449.21	344.41
Operating Profit (EBIT)	-542.70	-555.34	-487.34	-196.70	-340.74	-295.75
Other Income	--	--	--	--	--	4.60
Profit before Tax	-511.35	-512.44	-422.71	-145.19	-325.97	-291.16
Provision for Tax	0.10	0.10	0.07	0.03	0.02	-0.58
Profit after Tax (Net Income)	-511.45	-512.54	-422.77	-145.22	-325.99	-290.58
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-325.99	-290.58

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	835.18	1,013.76	1,229.68	1,030.95	1,042.43	962.29
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	232.69	32.74	42.29	44.98	53.89	63.63
Current Liabilities	90.08	98.35	102.21	77.98	363.92	378.25
Total Liabilities	1,248.04	1,144.85	1,374.18	1,153.92	1,460.24	1,404.16

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	404.03	244.20	509.74	89.78	87.92	506.93
Current Assets	753.93	900.66	864.44	1,064.14	1,372.32	897.23
Total Assets	1,248.04	1,144.85	1,374.18	1,153.92	1,460.24	1,404.16
Total Debt*	27.51	36.76	48.71	52.24	60.35	64.01
Net Current Assets	663.84	802.31	762.23	986.16	1,008.40	518.99

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-412.60	-347.69	-357.99	-244.72	-211.39
Cash Flow from Investing Activities	--	255.28	-88.76	249.31	-141.39	-21.63
Cash from Financing Activities	--	189.22	484.30	17.82	310.67	19.35
Net Cash Inflow / Outflow	--	--	--	--	--	-213.67

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-2.84	-2.92	-2.49	-1.05	-2.45	-2.38
Cash EPS ($)	--	-2.84	-2.43	-0.92	-2.38	-2.31
Adjusted Book Value ($)	--	5.78	7.23	7.46	7.85	7.88
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.35	-2.04	-2.59	-1.84	-1.73
Free Cash Flow per Share ($)	--	-2.41	-2.14	-2.68	-1.98	-1.80

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-44.02	-35.80	-13.29	-30.62	-25.88
ROE (%)	-55.32	-45.69	-37.40	-14.01	-32.52	-27.51
ROA (%)	-40.83	-40.69	-33.45	-11.11	-22.76	-19.32
EBIT Margin (%)	-14,188.37	--	--	-43.93	-300.54	-607.78
Net Margin (%)	-14,191.20	--	--	-43.94	-300.56	-545.63
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	-1.00	2.05	1.23	-0.86
EBIT Growth (%)	-6.76	-2.10	-245.66	55.46	-10.22	-571.56
Net Profit Growth (%)	-6.77	-21.23	-191.12	55.45	-12.19	-508.49
EPS Growth (%)	-1.07	-0.18	-1.37	0.57	-0.03	-5.29
Book Value Growth (%)	-25.57	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-5.65	-8.20	-20.43	-11.34	-18.75
Price / Book Value	4.36	2.86	2.82	2.88	3.54	5.66
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	86.48	-4.15	-5.44	-15.45	-7.67	-16.18
Close Price ($)	25.72	16.51	20.38	21.46	27.81	44.60
High Price ($)	26.36	24.35	33.33	33.31	47.47	84.25
Low Price ($)	12.58	10.57	14.56	15.45	20.24	41.10
Market Cap ($ Cr)	3,561.40	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.04	0.04	0.05	0.06	0.07
Short term debt to equity ratio	--	0.01	0.01	0.01	0.01	0.01
Current Ratio	8.37	9.16	8.46	13.65	3.77	2.37
Quick Ratio	8.32	--	--	13.65	3.78	--
Interest Coverage	--	--	--	--	-22.06	-22.43

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	108.96	--	--	1.03	8.56	2.52
Asset Turnover	0.00	--	--	0.25	0.08	0.03
Receivable days	--	--	--	7.02	17.69	25.90
Inventory Days	--	--	0.00	-54.59	-259.71	--
Payable days	--	236.25	483.10	134.00	196.57	190.47
Cash Conversion Cycle	--	--	--	-181.58	-438.58	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.